Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data,Expert Review of Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Expert Rev. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data
Expert Review of Gastroenterology & Hepatology ( IF 3.9 ) Pub Date : 2024-01-17 , DOI: 10.1080/17474124.2023.2295496
Amanda M. Johnson ₁ , Edward V. Loftus ₁

Affiliation

Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and more...

中文翻译：